AstraZeneca's cancer drug Imfinzi, combined with chemotherapy, received FDA approval to treat endometrial cancer with mismatch repair deficiency.
AstraZeneca's cancer drug Imfinzi, when combined with chemotherapy, received US FDA approval to treat adult patients with primary, advanced, or recurrent endometrial cancer with mismatch repair deficiency. This approval followed a late-stage trial showing a 58% risk reduction in disease progression or death when Imfinzi was used with chemotherapy drugs carboplatin and paclitaxel, compared to chemotherapy alone.
June 17, 2024
9 Articles